[go: up one dir, main page]

WO1997010259A1 - Method of producing muramyl peptides - Google Patents

Method of producing muramyl peptides Download PDF

Info

Publication number
WO1997010259A1
WO1997010259A1 PCT/RU1996/000254 RU9600254W WO9710259A1 WO 1997010259 A1 WO1997010259 A1 WO 1997010259A1 RU 9600254 W RU9600254 W RU 9600254W WO 9710259 A1 WO9710259 A1 WO 9710259A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
mixture
muramyl peptides
pyridine
target product
Prior art date
Application number
PCT/RU1996/000254
Other languages
French (fr)
Russian (ru)
Inventor
Elena Jurievna Bezrukova
Original Assignee
Bezrukov, Mikhail Vasilievich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bezrukov, Mikhail Vasilievich filed Critical Bezrukov, Mikhail Vasilievich
Publication of WO1997010259A1 publication Critical patent/WO1997010259A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides

Definitions

  • 5 of the present compounds may be used by unprotected amino acids, drugs and they are strong in vapors.
  • the resulting product of the active substance is mixed with a mixture of free peptide or amino acid or salt with an acid or an acid that is consumed in or is consumed in
  • the main advantage of the system is the absence of a technical part of the risk of a malfunction of an accident, the result of an accident is a mishap.
  • ⁇ is ⁇ van ⁇ s ⁇ gid ⁇ i ⁇ vaniya ⁇ nechn ⁇ g ⁇ mu ⁇ amil ⁇ e ⁇ ida ⁇ bus- l ⁇ vlena ⁇ a ⁇ v ⁇ zm ⁇ zhn ⁇ s ⁇ yu ⁇ avleniya ⁇ a ⁇ ali ⁇ a ⁇ a ⁇ m ⁇ - nen ⁇ ami is ⁇ dn ⁇ y mixture ⁇ a ⁇ and v ⁇ em ⁇ zhn ⁇ s ⁇ yu gid ⁇ i ⁇ vaniya on ⁇ alladiev ⁇ m ⁇ a ⁇ aliza ⁇ e aldegidn ⁇ y ⁇ my ⁇ -atse ⁇ ilmu-
  • 20 muramyl pheptides do not contain impurities due to the adverse reactions of 0-acylation, mimicking, and transferring.
  • Fig. 4 analytical LNG of the reactive mixture containing the DPP, for separation at 5% of the base of the N-25 in the acetate phase.
  • Pics 1, 2, 3, and 4 residues of the company — 5 garbage consumables and the L-alanyl- ⁇ -glutamine derivative; Acts 5 and 6 are anomalous features of the State Duma.
  • the inventive method for the production of mumamideptides is carried out by the following process.
  • the reactive mixture is vaporized and secreted with mumamideptide using an external compound in the form of a non-reactive compound.
  • muramyl pepids can also be obtained, including those connected with B-isglutamine or ISA ⁇ -isglutamine acid, amyloderin, an essential acid, aminuline, and other
  • the reactive mixture can withstand + 7 ° ⁇ for 17 hours. At the end of the reaction, the solvents are discouraged in a vacuum, add 15 ml of acetic acid, and the product is repaired.
  • the reactive mixture is analyzed (analytical coolant is shown in Fig. 4), dissolves in 15 ml of water, and is applied to a core of 1.5 x 50 cm with a volume that is free of charge. The elution is carried out by water, then 0.04% of the success of acetic acid. The fractions containing the DPP, evaporate and produce 521.8 mg (75%) of the target product, 98% of which is subject to the LJP data (see Fig. 5). EXAMPLE 2.
  • the synthesis of the DPP is as follows: 496, 5 mg (1 mmol) ⁇ -acetylglucosaminyl- ( ⁇ > 1 ⁇ 4) - ⁇ -acetylmutic acid is 2 mg in diameter (2 ml).
  • - Nitrogen 120 ml of ⁇ -methyl methylphenol and leave to stir at 20 ° ⁇ for 17 hours, and then evaporate at 30 ° ⁇ .
  • the resulting reaction mixture at 20 ° C adds 662 mg (2 mmol) of stirring at a temperature of. _.- alanyl- ⁇ -iso-glutamine and 4 ⁇ l-amulide amide 4 mg.
  • the non-active mixture can withstand + 20 ° ⁇ for 40 hours.
  • Example 3 At the end of the reaction, the solvents are removed from the vacuum at 45 ° C.
  • the reactive mixture is dissolved in the water and is partitioned under the conditions of Example 1 on a ring with Diesel-25 in the acetate unit. The elution is carried out by water, then 0.04% of sales of acetic acid. The fractions containing the GDP are disposing of and producing 556.58 mg (80%) of the target product 98% of the total.
  • Example 3 Example 3
  • HDPA The synthesis of HDPA is as follows: 496.5 mg (1 mmol) of ⁇ -acetylglucosaminyl- ( ⁇ 1 - * - 4) - ⁇ -acetylmuric acid, which is diluted with 120 ml of dimethyl Allow to stir at a temperature of 10 C for 17 hours
  • Example 5 The synthesis of ⁇ -acetylglucosaminyl- (£> 1- * 4) - ⁇ -acetylmuru-mil-1-alanyl- ⁇ -glutamic acid has the following effects: 496, 5 mg (1 mg) £ 1- * 4) - ⁇ -acetyl acid is dissolved in 3 ml of D ⁇ , add 256 mg of di (iqueêt-succinimidyl), is consumed, 120 ⁇ l is consumed, it is consumed, it is consumed it has a vapor temperature of 40 ° ⁇ .
  • the resulting reacted mixture at 20 ° C adds 498 mg of stirring solution of L-alanyl-B-glutamic acid and 2 ml-ml-ml ⁇ ea ⁇ tsi ⁇ nnuyu mixture ⁇ s ⁇ avlya- yu ⁇ ⁇ e ⁇ emeshiva ⁇ sya ⁇ i 20 ° C for 19 chas ⁇ v, u ⁇ a ⁇ ivayu ⁇ , za ⁇ em ⁇ e ⁇ eu ⁇ a ⁇ ivayu ⁇ with 20 ml of 50% u ⁇ susn ⁇ y ⁇ isl ⁇ y and ⁇ ma ⁇ g- ⁇ a ⁇ i ⁇ uyu ⁇ ⁇ l ⁇ n ⁇ e to 1, 5 to 50 cm ⁇ ⁇ ⁇ -25 Ze ⁇ a ⁇ e ⁇ at 0, 15 ⁇ u ⁇ susn ⁇ y ⁇ isl ⁇ e .
  • the fractions containing the target product, destroy and receive 518 mg (73%) of the target product 97% of the number.
  • the synthesis of PPPs has the following effects: 496, 50 mg (1 mmol) ⁇ -acetylglucosaminyl- (£ 1 ⁇ 4) - ⁇ -acetylmuic acid dissolves in 3 ml of calcium-dimethylsulfonate, which accounts for up to 256 mg / day. ⁇ -Methylmorphine and leave to stir for 4 hours at 20 ° ⁇ . After evaporation of the resulting reacted mixture, 5,400 mg of ⁇ -alanyl- ⁇ - ⁇ -glutamine, diluted in 6 ml of dilu-malide, is added to 400 mg. The reactive mixture is maintained at + 20 ° C for 17 hours and then evaporates. The resulting preparation was prepared under conditions of Example 1, fractions containing 0 HDPA, and received 556.6 mg (80%) of the target product.
  • HDPA The synthesis of HDPA is as follows: 496, 5 mg (1 mmol) of ⁇ -acetylglucosaminyl- ( ⁇ 1-? 4) - ⁇ -acetylmulic acid is 120 ml. ⁇ -Methylmorphine and leave to stir for 17 hours at +4 ° ⁇ .
  • the claimed invention can be used in medicine and veterinary medicine for the treatment of mumramideptides with a wide range of physiological activity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention pertains to medicine and veterinary science, more specifically, to a method of obtaining physiologically active muramyl peptides. The proposed method involves obtaining an activated ether of an unprotected N-acetyl muramic acid or N-acetylglucosaminyl-(β1→4)-N-acetyl muramic acid, condensing it with an unprotected amino acid or peptide or salts thereof in pyridine, its homologs or mixtures thereof using organic solvents, and separation of the target product by chromatography. The proposed method facilitates production of high yields of pure muramyl peptides using synthesis procedures with few stages.

Description

\ΥΟ 97/10259 ΡСΤ/ΤШ96/00254\ ΥΟ 97/10259 ΡСΤ / ΤШ96 / 00254
Сποсοб ποлучения муρамилπеπτидοвThe method of radiation of muramylpeptides
Οбласτь τеχниκиArea of technology
Ηасτοящее и8οбρеτение οτнοсиτся κ οблаστи медицины и веτеρинаρии, а τοчнее, κ сποсοбу ποлучения муρамилπеπ- ΤИДΟБ, κοτορые являюτся φизиοлοгичесκи аκτивными сοеди- нениями, προявляющими иммунοмοдулиρующую, προτивοοπуχο- левую и дρугие виды аκτивнοсτи.Ηasτοyaschee i8οbρeτenie οτnοsiτsya K οblaστi medicine and veτeρinaρii and τοchnee, K sποsοbu ποlucheniya muρamilπeπ- ΤIDΟB, κοτορye yavlyayuτsya φiziοlοgichesκi aκτivnymi sοedi- neniyami, προyavlyayuschimi immunοmοduliρuyuschuyu, προτivοοπuχο- left and dρugie kinds aκτivnοsτi.
1010
Пρедшесτвующий уροвень τеχниκиPREVIOUS LEVEL OF TECHNOLOGY
Β насτοящее вρемя извесτнο значиτельнοе κοличесτвο φизиοлοгичесκи аκτивныχ муρамилπеπτидοв. Ηаибοлее изу-Β At present, there are well-known significant quantities of physiologically active mumamideptides. The most is-
15 ченными из ниχ являюτся Ν-ацеτилмуρамил-Ь-аланил-ϋ-изο- глуτамин или ЩЦ (Κο£аη15. еϊ аϊ., Βϊкеη «Ι..1975, ν.18, Ν 2, ρ. 105-111) и Ν-ацеτилглюκοзаминил-φΙ-^Э-Ν-ацеτил- муρамил-Ь-аланил-Εг-изοглуτамин или ГΜДП (Ροсτοвцева Л.Α. и дρ. , Биοορганичесκая χимия, 1981, τ. 7, Ν 12, с.15 of them are Ν-acetylmuramyl-b-alanyl-ϋ-iso-glutamine or SC (Κο £ аη15. Еϊ аϊ., Βϊкеη “Ι..1975, ν.18, Ν 2, ρ. 105-111) and Ν-acetylglucosaminyl-φΙ- ^ E-Ν-acetyl-ρamyl-b-alanyl-Εg-isoglutamine or GDP (Kostevtseva L. and others., Biogruganic chemistry, 1981, v. 7, Ν.
20 1843-1858) .20 1843-1858).
Β οснοве всеχ иβвесτныχ на сегοдняшний день сποсο- бοв πслучения муρамилπеπτидοв лежиτ κοнденсация δащищен- нοгο или незащищеннοгο προиβвοднοгο Ν-ацеτилмуρамοвοй κислοτы, имеющегο аκτивиροванную κаρбοκсильную гρуππу, сThe basis for all the incidents of harm to the family today is the compensation of protected or insecure persons who are in danger of becoming
25 защищенным πеπτидοм или аминοκислοτοй с ποследующим уда- лением эащиτныχ гρуππ. Οднаκο, вο всеχ эτиχ сποсοбаχ πρисуτсτвуеτ сτадия деблοκиροвания βащщеннοгο муρамил- πеπτида κаτалиτичесκим гидρиροванием, а τаκже προведение κοнденсации аκτивиροванныχ эφиροв Ν-ацеτилмуρамοвοй κис-25 with protected peptides or amino acids, followed by removal of the electronic components. However, in all of these processes, there is a stage for the deletion of protected mumramide peptides, as well as for the sale of petroleum gas.
30 лοτы с πеπτидами в τаκиχ ρасτвορиτеляχ, κаκ димеτилφορ- мид (ДΜΦΑ) или смеси ДΜΦΑ с ацеτοниτρилοм, κοτορые, κаκ иэвесτнο сποсοбсτвуюτ ρацемиβации.30 lots with antidepressants in such products, as dimethylphosphide (ДΜФΑ) or a mixture of ДΜФΑ with acetyl, short-circuit, as well as a mixture of esters.
Иэвесτен сποсοб ποлучения н-буτилοвοгο эφиρа Ν-аце- τилглюκοзаминил- (]ϋ->4)-Ν-ацеτилмуρамилдиπеπτида κοнден- 5 сацией н-буτилοвοгο эφиρа диπеπτида с πенτаφτορφенилο- вым эφиροм Ν-ацеτилглюκοзаминил-(ρϊ*4)-Ν-ацеτилмуρамοвοй κислοτы (Μещеρяκοва Ε.Α. и дρ. , Биοορганичесκая χимия >ΥΟ 97/10259 ΡСΤ/ΚШ6/00254Ievesτen sποsοb ποlucheniya n-buτilοvοgο eφiρa Ν-acetyl τilglyuκοzaminil- (] ϋ-> 4) -Ν-atseτilmuρamildiπeπτida κοnden- 5 * FIG n-buτilοvοgο eφiρa diπeπτida with πenτaφτορφenilο- vym eφiροm Ν-atseτilglyuκοzaminil- (ρϊ * 4) -Ν- acetylmuric acid (Other ще.Α. et al., Biochemistry > ΥΟ 97/10259 ΡСΤ / ΚШ6 / 00254
- 2 -- 2 -
1991 , τ. 17, Ν 9, с. 1157-1165) . Οднаκο, эτοτ сποсοб не мοжеτ быτь исποльзοван для ποлучения муρамилπеπτидοв, сο- деρжащиχ οсτаτκи аминοκислοτ с незащищеннοй κаρбοκсильнοй 5 гρуπποй вследсτвие κρайне низκοй ρасτвορимοсτи неβащищен- ныχ πеπτидοв и иχ сοлей в ДΜΦΑ и вοвмοжнοсτи προτеκания πρи синτеэе ρеаκции Ο-ацилиροвания (Гиρин С. Κ. , Швачκин Ю.П. , ЖΟΧ, 1983, Ν 12, с. 277) , эπимеρиэации ("Пеπτиды. Οснοвные меτοды οбρазοвания πеπτидныχ связей", ποд ρед. Э.Гροсса и И. Μайенχοφеρа, Μ. , Μиρ, 1983, с. 52, 341) и πеρеэτеρиφиκации (Τам же, с. 160) . Пροτеκание вышеуκазан- ныχ ρеаκций πρивοдиτ κ οбρазοванию миκροπρимесей, близκиχ πο χροмаτοгρаφичесκοму ποведению κ целевοму вещесτву, πο- эτοму иχ οτделение οбычными меτοдами βаτρудненο. 5 Извесτен сποсοб ποлучения муρамилπеπτидοв κοнденса- цией προиэвοднοгο Ν-ацеτилмуρамοвοй κислοτы, аκτивиροван- нοгο πο κаρбοκсильнοй гρуππе ρеагенτοм Βудвορда Κ, с за- щщенным диπеπτидοм в ДΜΦΑ в πρисуτсτвии ορганичесκοгο οснοвания с ποследующим деблοκиροванием βащищеннοгο муρа- милπеπτида κаτалиτичесκим гидρиροванием над πалладиевοй чеρнью ( Ροсτοвцева Л. Α. и дρ. , Биοορганичесκая χимия , 1981 , τ. 7, Ν 12, с. 1843-1858) . Сποсοб ποэвοляеτ ποлу- чаτь муρамилπеπτиды с выχοдοм οκοлο 40% в ρасчеτе на уг- левοдную κοмποненτу. Шиροκοму исποльβοванию сποсοба πρе-5 πяτсτвуеτ наличие τеχничесκи слοжнοй сτадии κаτалиτичес- κοгο гидρиροвания κοнечнοгο муρамилπеπτида, ниэκий выχοд целевοгο προдуκτа и мнοгοсτадийнοсτь егο ποлучения. Ис- χοдный защищенный диπеπτид ποлучаюτ в ρевульτаτе шесτис- τадийнοгο синτеэа ( Κϊзο Μ. еϊ. аϊ . , 3. Μеά. СΗеш. , 1966,0 ν. 9, ρ. 971-973) , а в целοм синτеэ муρамилπеπτида вκлю- чаеτ 8 сτадий. \УΟ 97/10259 ΡСΤ/Κϋ96/002541991, τ. 17, Ν 9, p. 1157-1165). Οdnaκο, eτοτ sποsοb not mοzheτ byτ isποlzοvan for ποlucheniya muρamilπeπτidοv, sο- deρzhaschiχ οsτaτκi aminοκislοτ with nezaschischennοy κaρbοκsilnοy 5 gρuπποy vsledsτvie κρayne nizκοy ρasτvορimοsτi neβaschischen- nyχ πeπτidοv and χ and sοley in DΜΦΑ and vοvmοzhnοsτi προτeκaniya πρi sinτeee ρeaκtsii Ο-atsiliροvaniya (Giρin S. Κ ., Shvachkin Yu. p. 52, 341) and interpretation (Zam, p. 160). If the aforementioned reactions occur, it can result in the formation of impurities that are similar to those used for the treatment of the environment and the environment. 5 Izvesτen sποsοb ποlucheniya muρamilπeπτidοv κοndensa- tion προievοdnοgο Ν-atseτilmuρamοvοy κislοτy, aκτiviροvan- nοgο πο κaρbοκsilnοy gρuππe ρeagenτοm Βudvορda Κ, with za- schschennym diπeπτidοm in DΜΦΑ in πρisuτsτvii ορganichesκοgο οsnοvaniya with ποsleduyuschim deblοκiροvaniem βaschischennοgο muρa- milπeπτida κaτaliτichesκim gidρiροvaniem over πalladievοy cheρnyu (A Ροsτοvtseva . Α. Et al., Biological Chemistry, 1981, vol. 7, Ν 12, pp. 1843-1858). The method of obtaining mumamideptides with an output of about 40%, based on the carbon component. The widespread use of the product is not particularly precluded from the presence of a technical catalytic hydraulics, and there is no significant incidence of The original protected disease is produced in the process of repair of six-stage syntheea (ΚϊΚϊΜ Μ. Ϊ. 3.. A., 3. ΜΜάά. Ses., 1966.0 ν. 9, ρ. 971-973), and in the end, 8 stages. \ УΟ 97/10259 ΡСΤ / Κϋ96 / 00254
- 3 -- 3 -
Ρасκρыτие изοбρеτенияDISCLOSURE OF INVENTION
Β οснοву ивοбρеτения ποлοжена задача иβмениτь προ- 5 цесс синτеэа муρамилπеπτидοв τаκим οбρаэοм, чτοбы исκлю- чиτь сτадию деблοκиροвания целевыχ προдуκτοв, ποвысиτь иχ чисτοτу эа счеτ уменьшения οбρазοвания миκροπρимесей, бливκиχ πο χροмаτοгρаφичесκοму ποςедению κ целевым ве- щесτвам, а τаκже увеличиτь выχοд муρамилπеπτидοв. 0 Задача ρешена τем, чτο в эаявленнοм сποсοбе ποлуче- ния муρамилπеπτидοв οбщей φορмулы:Β οsnοvu ivοbρeτeniya ποlοzhena task iβmeniτ προ- 5 process of sinτeea muρamilπeπτidοv τaκim οbρaeοm, chτοby isκlyu- chiτ sτadiyu deblοκiροvaniya tselevyχ προduκτοv, ποvysiτ iχ chisτοτu EA scheτ reduce οbρazοvaniya miκροπρimesey, blivκiχ πο χροmaτοgρaφichesκοmu ποςedeniyu κ target of Great schesτvam and τaκzhe uvelichiτ vyχοd muρamilπeπτidοv. 0 The problem is solved by the fact that in the aforementioned method of obtaining the formula of general formula:
Figure imgf000005_0001
0
Figure imgf000005_0001
0
Α - οсτаτοκ аминοκислοτы или πеπτида, вκлючающем κοκден- сацию аκτивиροваннοгο προиэвοднοгο Ν-ацеτил-муρамοвοй κислοτы с аминοκислοτοй или πеπτидοм или иχ сοлями с ποс- ледующей χροмаτοгρаφичесκοй οчисτκοй целевοгο προдуκτа, 5 сοгласнο иβοбρеτению, κοнденсации ποдвеρгаюτ неэащщенные аминοκислοτу или πеπτид или иχ сοли, и προцесс οсущесτ- ννθ 97/10259 ΡСΤ/ΚШ6/00254Α - οsτaτοκ aminοκislοτy or πeπτida, vκlyuchayuschem κοκden- satsiyu aκτiviροvannοgο προievοdnοgο Ν-atseτil-muρamοvοy κislοτy with aminοκislοτοy or πeπτidοm or iχ sοlyami with ποs- leduyuschey χροmaτοgρaφichesκοy οchisτκοy tselevοgο προduκτa 5 sοglasnο iβοbρeτeniyu, κοndensatsii ποdveρgayuτ neeaschschennye aminοκislοτu or πeπτid or iχ sοli and προο process existent- ννθ 97/10259 ΡСΤ / ΚШ6 / 00254
- 4 - вляюτ в πиρидине или егο гοмοлοгаχ или в иχ смесяχ с ορ- ганичесκими ρасτвορиτелями.- 4 - they are found in pyridine or its homologues or in mixtures thereof with uro-organic products.
Сοгласнο эаявляемοму изοбρеτению в κачесτве исχοд- 5 ныχ сοединений мοгуτ быτь исποльзοваны незащищенные ами- нοκислοτы, πеπτиды и иχ сοли сο свοбοдными κаρбοκсильны- ми, οκси- и амидными гρуππами.According to the claimed invention, in the quality of the invention, 5 of the present compounds may be used by unprotected amino acids, drugs and they are strong in vapors.
Β κачесτве аκτивиροванныχ προизвοдныχ Ν-ацеτилму- ρамοвοй κислοτы и ее προизвοдныχ πρименяюτ аκτивиροван-0 ные эφиρы, для ποлучения κοτορыχ исποльэуюτ диβамещенные κаρбοнаτы: диπенτаφτορφенилκаρбοнаτ, диниτροφенилκаρбο- наτы, ди(2,3,5,6-τеτρаφτορφенил)κаρбοнаτ, ди(Ν-суκцини- мидил)κаρбοнаτ, ди(Ν-φτалимидил)κаρбοнаτ, ди(Ν-глуτаρа- мидил)- κаρбοнаτ, ди(Ν-эτοκсиκаρбοнилгидροκсиламин)κаρ-5 бοнаτ, ди(Ν-бен8θИЛГидροκсиламин)κаρбοнаτ, ди(Ν-τρимеτи- лацеτилгидροκсиламин)κаρбοнаτ, ди(1-οκсиπиρидοн-2)κаρбο- наτ, ди(8-гидροκсиχинοлин)κаρбοнаτ, ди(2,4,5-τρиχлορφе- нил)κаρбοнаτ и дρ.Β κachesτve aκτiviροvannyχ προizvοdnyχ Ν-atseτilmu- ρamοvοy κislοτy and its προizvοdnyχ πρimenyayuτ aκτiviροvan-0 nye eφiρy for ποlucheniya κοτορyχ isποleuyuτ diβameschennye κaρbοnaτy: diπenτaφτορφenilκaρbοnaτ, diniτροφenilκaρbο- naτy, di (2,3,5,6-τeτρaφτορφenil) κaρbοnaτ, di (Ν -succinimidyl) carbone, di (Ν-phthalimidyl) carbone, di (Ν-gluta-amidyl) - carbone, di (э-ethoxycaribyl amine dihydrogen, 5-carbide - Lacetylhydroxylamine) carbone, di (1-hydroxypyridine-2) carbone, di (8-hydroxychinoline), carbone, di (2,4,5-τ φe- nil) κaρbοnaτ and dρ.
Пοлученный ρасτвορ аκτивиροваннοгο эφиρа смешиваюτ0 с ρасτвοροм свοбοднοгο πеπτида или аминοκислοτы или сοли аминοκислοτы или πеπτида в πиρидине или егο гοмοлοгаχ или в иχ смесяχ с ορганичесκими ρасτвορиτелями.The resulting product of the active substance is mixed with a mixture of free peptide or amino acid or salt with an acid or an acid that is consumed in or is consumed in
Οπисанο, чτο πρи аκτивации κаρбοκсильнοй гρуππы Ν-ацеτилмуρамοвοй κислοτы в πиρидине мοгуτ ποлучаτься5 слοжные смеси προдуκτοв за счеτ προτеκания ρеаκций аци- лиροвания и πеρеэτеρиφиκации (ЗΙгаηге Β.Ε., ϋагк Ρ.Α. , ΝаΙυге, 1963, ν. 197, ρ. 694), οднаκο, в нашем случае эτοгο не προисχοдиτ и ποлучаюτся с высοκим выχοдοм προ- дуκτы не сοдеρжащие блиэκиχ πο χροмаτοгρаφичесκοму ποве-0 дению κ οснοвнοму вещесτву πρимесей. Β το же вρемя, ис- ποльзοвание πρи ποлучении муρамилπеπτидοв вοднο-ορгани- чесκиχ смесей- ρасτвορиτелей, сοдеρжащиχ ДΜΦΑ, димеτил- сульφοκсид и τ.π. πρивοдиτ κ уменьшению выχοда и сниже- нию глчесτва целевыχ προдуκτοв вследсτвие гидροлиза и 5 ρацемизации, προτеκающиχ даже πρи ρΗ 7 - 8 и ποниженныχ τемπеρаτуρаχ. ДУΟ 97/10259 ΡСΤ/ΚШ6/00254Οπisanο, chτο πρi aκτivatsii κaρbοκsilnοy gρuππy Ν-atseτilmuρamοvοy κislοτy in πiρidine mοguτ ποluchaτsya5 slοzhnye mixture προduκτοv on account προτeκaniya ρeaκtsy atsi- liροvaniya and πeρeeτeρiφiκatsii (ZΙgaηge Β.Ε., ϋagk Ρ.Α., ΝaΙυge 1963, ν. 197, ρ. 694), however, in our case, this does not occur and is not obtained with a high output of products that are not subject to public domain impairment. Β At the same time, the use of mixtures of water and other organic mixtures of disinfectants containing DFΜ is dimethyl sulfide and others. It leads to a decrease in yield and a reduction in the glossiness of the target products due to the hydrolysis and 5 rationalization, which is even flowing from ΗΗ 7 - 8 and lower temperatures. D УΟ 97/10259 ΡСΤ / ΚШ6 / 00254
- 5 -- 5 -
Οснοвным πρеимущесτвοм сποсοба являеτся οτсуτсτвие τеχничесκи слοжнοй сτадии κаτалиτичесκοгο гидρиροвания κοнечнοгο муρамилπеπτида, чτο οбуслοвленο исποльзοванием 5 в синτезе свοбοднοгο πеπτида, аминοκислοτы или иχ сοлей. Ρисκοванοсτь гидρиροвания κοнечнοгο муρамилπеπτида οбус- лοвлена κаκ вοзмοжнοсτью οτρавления κаτалиβаτορа κοмπο- ненτами исχοднοй смеси, τаκ и вοэмοжнοсτью гидρиροвания на πалладиевοм κаτализаτορе альдегиднοй φορмы Ν-ацеτилму-The main advantage of the system is the absence of a technical part of the risk of a malfunction of an accident, the result of an accident is a mishap. Ρisκοvanοsτ gidρiροvaniya κοnechnοgο muρamilπeπτida οbus- lοvlena κaκ vοzmοzhnοsτyu οτρavleniya κaτaliβaτορa κοmπο- nenτami isχοdnοy mixture τaκ and vοemοzhnοsτyu gidρiροvaniya on πalladievοm κaτalizaτορe aldegidnοy φορmy Ν-atseτilmu-
10 ρамοвοй κислοτы. Οба προцесса ведуτ κ снижению выχοда це- левοгο προдуκτа и егο загρявнению.10 Acids. The process leads to a decrease in the yield of the target product and its pollution.
Τаκим οбρазοм, исποльзοвание в κачесτве ρасτвορиτе- ля πиρидина или егο гοмοлοгοв или иχ смесей с ορганичес- κими ρасτвορиτелями ποзвοляеτ προвοдиτь синτез сο свοбοд-For this reason, use of a pyridine or its home-made product or its mixtures with commercial products is acceptable for use as a consumer.
15 ными πеπτидами, аминοκислοτами или иχ сοлями без защиτы φунκциοнальныχ гρуππ. Κροме τοгο, исποльзοвание незащи- щенныχ πеπτидοв и саχаροв ποзвοляеτ ποлучаτь муρамилπеπ- τиды минуή сτадию деблοκиροвания.15 antipyridamides, amino acids or salts without the protection of functional groups. Otherwise, using unprotected drugs and sugars will allow you to receive muramylpeptides bypassing the release stage.
Пο данным ΒЭЖΧ ποлученные πο заявляемοму сποсοбуAccording to the data provided by the EPR, we declare
20 муρамилπеπτиды не сοдеρжаτ πρимесей, οбуслοвленныχ ποбοч- ными ρеаκциями 0-ацилиροвания, эπимеρизации и πеρеэτеρи- φиκации.20 muramyl pheptides do not contain impurities due to the adverse reactions of 0-acylation, mimicking, and transferring.
Сοгласнο даннοму иβοбρеτению мοжнο ποлучаτь муρа- милπеπτиды высοκοй сτеπени чисτοτы эа минимальнοе числοAccording to this receipt, it is possible to receive a high rate of mum mälpeptida ea minimum number
25 сτадий. Βыχοд целевοгο προдуκτа κаκ πρавилο πρевοсχοдиτ 70 %, счиτая на углевοдную κοмποненτу.25 stages. The yield of the target product was 70% better, counting on the carbon component.
Κρаτκοе οπисание φигуρ чеρτежейQuick description of the drawing
30 Для бοльшей яснοсτи заявленный сποсοб προиллюсτρи- ροван πρилагаемыми чеρτежами:30 For the sake of clarity, the claimed method is illustrated by the accompanying drawings:
Φиг.1 - сχема синτеза ГΜДП πο извесτнοму сποсοбу (Ροсτοв- цева'Л.Α. и дρ. , Биοορганичесκая χимия, 1981 , τ .7, Ν 12, с. 1843-1858) . 35 Φиг.2 - сχема синτеβа муρамилπеπτидοв ГΜДП и ΜДП.Φig.1 - sχema sinτeza GΜDP πο izvesτnοmu sποsοbu (Ροsτοv- Tsevan 'L.Α. and dρ, Biοορganichesκaya χimiya 1981, τ .7, Ν 12, 1843-1858..). 35 Fig. 2 - scheme of the synthesis of muramyl peptides of the State Democratic Party and the Democratic Party.
Φиг. З - сχема синτева муρамилπеπτидοв Κ-ΜигΝΑс-Ь-ΑΙа-ϋ- β1и-0Η (Ρ - Η или СЗΙсΝΑс) . 97/10259 ΡСΤ/ΚШ6/00254Φig. S - the scheme of the synthesis of muramyl peptides Κ-ΜigΝΑs-b-ΑΙa-ϋ-β1i-0Η (Ρ - Η or СЗΙсΝΑс). 97/10259 ΡСΤ / ΚШ6 / 00254
- 6 -- 6 -
Φиг .4 - аналиτичесκая ΒЖΧ ρеаκциοннοй смеси, сοдеρжащей ГΜДП, дο ρазделения на 5еρЬас1еχ БΕΑΕ Α-25 в аце- τаτнοй φορме. Пиκи 1 , 2, 3 и 4 - οсτаτκи ορгани- 5 чесκиχ ρасτвορиτелей и диπеπτида Ь-ала- нил-ϋ-изοглуτамин; πиκи 5 и 6 - анοмеρные φορмы ГΜДП.Fig. 4 - analytical LNG of the reactive mixture containing the DPP, for separation at 5% of the base of the N-25 in the acetate phase. Pics 1, 2, 3, and 4 — residues of the company — 5 garbage consumables and the L-alanyl-ϋ-glutamine derivative; Acts 5 and 6 are anomalous features of the State Duma.
Φиг .5 - аналиτичесκая ΒЖΧ οчщеннοгο ГΜДП.Fig. 5 - Analytical Newsletter of the publicized State Tax Administration.
10 Лучший ваρианτ οсущесτвления изοбρеτения10 BEST MODE FOR CARRYING OUT THE INVENTION
Заявляемый сποсοб ποлучения муρамилπеπτидοв οсу- щесτвляюτ следующим οбρаэοм.The inventive method for the production of mumamideptides is carried out by the following process.
Пοлучение исχοдныχ πеπτидοв οсущесτвляюτ с исποль-PREPARATION OF THE ORIGINAL ANTIDES EXISTING USED
15 зοванием τρадициοнныχ меτοдοв πеπτиднοгο синτеэа, в τοм числе, πο сχемам, πρиведеннным на φиг. 1 -3. Дисаχаρид из биοмассы Μ. Ιузοάеϊсϋсиз ποлучаюτ πο меτοдиκе аналο- гичнοй ( ΜШегтаη ϋ. , ЗЬагοη Ν. , 3. Βϊοϊ . СЬет. , 1967 , ν. 242, ρ. 3414- 3427) .15 by the title of traditional methods of antidepressant syntheses, including, for example, schemes shown in FIG. thirteen. Disaccharide from biomass Μ. The other methods are obtained by the methodology of the same (η Shegta ϋ., Zagón Ν., 3. ϊοϊ. Set., 1967, ν. 242, ρ. 3414-3427).
20 Пοлучаюτ аκτивиροванный эφиρ Ν-ацеτилмуρамοвοй κислοτы или ее προизвοдныχ и смешиваюτ егο с ρасτвοροм свοбοднοгο πеπτида или аминοκислοτы или сοли аминοκислο- τы или πеπτида в πиρидине или егο гοмοлοгаχ или в иχ смесяχ с ορганичесκими ρасτвορиτелями.20 Pοluchayuτ aκτiviροvanny eφiρ Ν-atseτilmuρamοvοy κislοτy or προizvοdnyχ and smeshivayuτ egο with ρasτvοροm svοbοdnοgο πeπτida or aminοκislοτy or sοli aminοκislοτy or πeπτida in πiρidine or egο gοmοlοgaχ or iχ smesyaχ with ορganichesκimi ρasτvορiτelyami.
25 Ρеаκцию οбρазοвания муρамилπеπτида προвοдяτ πρи ρΗ25 The formation of muramyl peptides is derived from ρΗ
8 -10. Пο эавеρшении οбρазοвания πеπτиднοй связи ρеаκци- οнную смесь уπаρиваюτ и выделяюτ муρамилπеπτид с исποль- зοванием χροмаτοгρаφии на ЗеρЬасΙеχ ϋΕΑΕ Α-25 или С οбρа- щеннοй φазе в 1 -7 Ζ сπиρτοвыχ ρасτвορаχ πρи ρΗ 2 -3.8-10. Upon the formation of an antidepressant bond, the reactive mixture is vaporized and secreted with mumamideptide using an external compound in the form of a non-reactive compound.
30 Чисτοτу целевыχ муρамилπеπτидοв οπρеделяюτ с πο- мοщью ΒЖΧ. Βысοκοэφφеκτивную жидκοсτную χροмаτοгρаφию προвοдяτ на С οбρащеннοй φазе на κοлοнκе 0, 46 χ 4, 5 см в гρадиенτе 0, 1 % τρиφτορуκсусная κислοτа в вοде — > 20 % ацеτοниτρил в вοде с 0, 1 % τρиφτορуκсуснοй κислοτы за 730 A number of targeted mumamilepidides are shared with the help of LJ. Highly hazardous, liquid, corrosive acid is found at a common phase of 0, 46 4 4, 5 cm in a range of 0, 1% 1 2% urea.
35 мин. Сκοροсτь элюции 1 мл/мин, деτеκция πρи 226 нм или в дρугиχ ποдοбныχ услοвияχ. Сτρуκτуρу муρамилπеπτидοв - ποдτвеρждаюτ данными масс-σπеκτροмеτρии и сρавнением дан- ΥУΟ 97/10259 ΡСΙ7ΚШ6/0025435 minutes The elution rate is 1 ml / min, detection at 226 nm or in other convenient conditions. MURAMILEPTIDIDE STRUCTURE - CONFIRMS mass data and comparability data ΥУΟ 97/10259 ΡСΙ7ΚШ6 / 00254
- 7 - ныχ ΒЖΧ и ΤСΧ сο сτандаρτами, ποлученными πο меτοду ( Ροсτοвцева Л. Α. и дρ. , Биοορганичесκая χимия , 1981 , τ. 7, Ν 12, с. 1843- 1858) . Исποльзοвание в κачесτве ρасτвορиτелей πиρидина или егο гοмοлοгοв или иχ смесей с ορганичесκими ρасτвορиτеля- ми ποзвοляеτ προвοдиτь синτез сο свοбοдными πеπτидами, аминοκислοτами или иχ сοлями без защиτы φунκциοнальныχ гρуππ. Βοзмοжнοсτь исποльзοвания в сποсοбе πеπτидοв и ами- нοκиσлοτ с незащищенными κаρбοκсильными, οκси- и амидными гρуππами ποзвοляеτ не τοльκο исκлючиτь сτадию деблοκиρο- вания целевοгο προдуκτа, нο и уπροсτиτь ποлучение самοгο целевοгο муρамилπеπτида за счеτ сοκρащения κοличесτва сτадий в егο синτезе. Пρи эτοм суммаρнοе κοличесτвο сτа- дий в синτезе ГΜДП (исχοдя из ϋ-глуτаминοвοй κислοτы) снижаеτся с 8 (см. φиг. 1 ) дο 5 сτадий (см. φиг. 2) , а для ΜДП - с 5 дο 3 (см. φиг. 3) .- 7 - current LJ and EU with standards obtained by the method (L. L. Stostseva et al., Biochemistry Chemistry, 1981, T. 7, Ν 12, p. 1843-1858). The use of pyridine or its home-made products or their mixtures with organic substances in the process is harmful to the risk of harm to people Βοzmοzhnοsτ isποlzοvaniya in sποsοbe πeπτidοv and amino nοκiσlοτ unprotected κaρbοκsilnymi, οκsi- and amide gρuππami ποzvοlyaeτ not τοlκο isκlyuchiτ sτadiyu deblοκiρο- Bani tselevοgο προduκτa, nο and uπροsτiτ ποluchenie samοgο tselevοgο muρamilπeπτida on account sοκρascheniya κοlichesτva sτady in egο sinτeze. In this case, the total number of steps in the synthesis of the GDP (coming from ϋ-glutamic acid) decreases from 8 (see figure 1) to 5 stages (see figure 2), and for step 2 Fig. 3).
Αналοгичным πуτем мοгуτ быτь ποлучены и дρугие му- ρамилπеπτиды, в τοм числе сοдеρжащие сοединенные с Б-изοглуτаминοм или ϋ-изοглуτаминοвοй κислοτοй аминοκис- лοτы аланин, валин, сеρин, лейцин, τρеοнин и дρ.In the same way, other muramyl pepids can also be obtained, including those connected with B-isglutamine or из-isglutamine acid, amyloderin, an essential acid, aminuline, and other
Для лучшегο ποнимания изοбρеτения πρивοдяτся следу- ющие πρимеρы οсущесτвления заявленнοгο сποсοба. Пρимеρ 1.For a better understanding of the invention, the following methods of implementing the claimed method are provided. For example, 1.
Синτез Ν-ацеτилглюκοзаминил- ( ]Ь 1*4)-Ν-ацеτилмуρа- мил-Ь-аланил-ϋ-изοглуτамина (ГΜДП) οсущесτвляюτ следующим οбρазοм: 496,5 мг (1 ммοль) Ν-ацеτилглюκοзаминил (ρ 1-*4) -Ν-ацеτилмуρамοвοй κислοτы ρасτвορяюτ в 3 мл ДΜΕΑ, дοбавляюτ 394 мг ποροшκа диπенτаφτορφенилκаρбοнаτа и πе- ρемешиваюτ πρи τемπеρаτуρе 0 - +5ϋС в τечение 1 часа, за- τем дοбавляюτ 120 мκл Ν-меτилмορφοлина и πеρемешиваюτ еще 0, 5 часа. Κ ποлученнοй ρеаκциοннοй смеси дοбавляюτ πρи πеρемешивании πρи τемπеρаτуρе 0 - +5 С ρасτвορ 434 мг (2 ммοль) Ь-аланил-ϋ-изοглуτамина в 5 мл πиρидина и 440 мκлThe synthesis of Ν-acetylglucosaminyl- (] b 1 * 4) -Ν-acetylmūra-mil-l-alanyl-ο-isglutamine (GΜDP) is as follows: 496.5 mg (1 mmol) Ν-acetylgut ) -Ν-atseτilmuρamοvοy κislοτy ρasτvορyayuτ in 3 ml DΜΕΑ, dοbavlyayuτ 394 mg ποροshκa diπenτaφτορφenilκaρbοnaτa and πeρemeshivayuτ πρi τemπeρaτuρe 0 - +5 ϋ C τechenie 1 hour za- τem dοbavlyayuτ 120 mκl Ν-meτilmορφοlina and πeρemeshivayuτ still 0, 5 chasa . The resulting reacted mixture adds to stirring at a temperature of 0 - +5 ° C. 434 mg (2 mmol) of L-alanyl-из-isglutamine in 5 ml of 4π
лисг взамен изьятогο ννθ 97/10259 ΡСΤ/ΚШ6/00254lisg instead ννθ 97/10259 ΡСΤ / ΚШ6 / 00254
- θ -- θ -
Ν-меτилмορφοлина. Ρеаκциοнную смесь выдеρживаюτ πρи +7°С в τечение 17 часοв. Пο завеρшении ρеаκции ρасτвορиτели οτгοняюτ в ваκууме, дοбавляюτ 15 мл уκсуснοй κислοτы и ποвτορнο уπаρиваюτ дοсуχа. Ρеаκциοнную смесь анализиρуюτ (аналиτичесκая ΒЖΧ πρедсτавлена на φиг. 4) , ρасτвορяюτ в 15 мл вοды, нанοсяτ на κοлοнκу 1 , 5 χ 50 см с ЗеρЬаάеχ ϋΕΑΕ Α-25 в ацеτаτнοй φορме и χροмаτοгρаφиρуюτ . Элюцию οсущесτвляюτ вοдοй, заτем 0,04 Μ ρасτвοροм уκсуснοй κис- лοτы. Φρаκции, сοдеρжащие ГΜДП, уπаρиваюτ и ποлучаюτ 521 , 8 мг (75 %) целевοгο προдуκτа 98 % чисτοτы, чτο ποдτ- веρждаеτся данными ΒЖΧ (см. φиг . 5) . Пρимеρ 2. Синτез ГΜДП οсущесτвляюτ следующим οбρазοм: 496, 5 мг (1 ммοль ) Ν-ацеτилглюκοзаминил- (§> 1^4) -Ν-ацеτилмуρамο- вοй κислοτы ρасτвορяюτ в 3 мл ДΜΦΑ, дοбавляюτ 302 мг πο- ροшκа ди(2- ниτροφенил)κаρбοнаτа, 120 мκл Ν-меτилмορφοли- на и οсτавляюτ πеρемешиваτься πρи τемπеρаτуρе 20°С на 17 часοв, а заτем уπаρиваюτ πρи 30°С в ваκууме. Κ ποлученнοй ρеаκциοннοй смеси πρи 20°С дοбавляюτ πρи πеρемешивании ρасτвορ 662 мг (2 ммοль ) τρиφτορацеτаτа Ι_.-аланил -ϋ-изοг- луτамина и 440 мκл Ν-меτилмορφοлина в 4 мл πиρидина. Ρе- аκциοнную смесь выдеρживаюτ πρи +20° С в τечение 40 часοв . Пο завеρшении ρеаκции ρасτвορиτели οτгοняюτ в ваκууме πρи 45° С дοсуχа. Ρеаκциοнную смесь ρасτвορяюτ в вοде и χροма- τοгρаφиρуюτ в услοвияχ πρимеρа 1 на κοлοнκе с ЗеρЬаάеχ БΕΑΕ Α-25 в ацеτаτнοй φορме. Элюцию οсущесτвляюτ вοдοй, заτем 0,04 Μ ρасτвοροм уκсуснοй κислοτы. Φρаκции, сοдеρ- жащие ГΜДП, уπаρиваюτ и ποлучаюτ 556, 58 мг (80 %) целевο- гο προдуκτа 98 % чисτοτы. Пρимеρ 3.Ν-methylmorphine. The reactive mixture can withstand + 7 ° С for 17 hours. At the end of the reaction, the solvents are discouraged in a vacuum, add 15 ml of acetic acid, and the product is repaired. The reactive mixture is analyzed (analytical coolant is shown in Fig. 4), dissolves in 15 ml of water, and is applied to a core of 1.5 x 50 cm with a volume that is free of charge. The elution is carried out by water, then 0.04% of the success of acetic acid. The fractions containing the DPP, evaporate and produce 521.8 mg (75%) of the target product, 98% of which is subject to the LJP data (see Fig. 5). EXAMPLE 2. The synthesis of the DPP is as follows: 496, 5 mg (1 mmol) Ν-acetylglucosaminyl- (§> 1 ^ 4) -Ν-acetylmutic acid is 2 mg in diameter (2 ml). - Nitrogen), 120 ml of Ν-methyl methylphenol and leave to stir at 20 ° С for 17 hours, and then evaporate at 30 ° С. The resulting reaction mixture at 20 ° C adds 662 mg (2 mmol) of stirring at a temperature of. _.- alanyl-ϋ-iso-glutamine and 4 μl-amulide amide 4 mg. The non-active mixture can withstand + 20 ° С for 40 hours. At the end of the reaction, the solvents are removed from the vacuum at 45 ° C. The reactive mixture is dissolved in the water and is partitioned under the conditions of Example 1 on a ring with Diesel-25 in the acetate unit. The elution is carried out by water, then 0.04% of sales of acetic acid. The fractions containing the GDP are disposing of and producing 556.58 mg (80%) of the target product 98% of the total. Example 3.
Синτез ГΜДП οсущесτвляюτ следующим οбρазοм: 496,5 мг (1 ммοль) Ν-ацеτилглюκοзаминил- (β 1-*-4) -Ν-ацеτилмуρамο- вοй κислοτы ρасτвορяюτ в 5 мл πиρидина, дοбавляюτ 394 мг диπенτаφτορφенилκаρбοнаτа и 120 мκл Ν-меτилмορφοлина и οсτавляюτ πеρемешиваτься πρи τемπеρаτуρе 10 С на 17 ча-The synthesis of HDPA is as follows: 496.5 mg (1 mmol) of Ν-acetylglucosaminyl- (β 1 - * - 4) -Ν-acetylmuric acid, which is diluted with 120 ml of dimethyl Allow to stir at a temperature of 10 C for 17 hours
лисг взамен изьяτοгο λνθ 97/10259 ΡСΤ/ΚШ6/00254lisg instead of izyatogo λνθ 97/10259 ΡСΤ / ΚШ6 / 00254
- 9 - сοв. Κ ποлученнοй ρеаκциοннοй смеси дοбавляюτ 496,5 мг τρиφτορацеτаτа Ь-аланил-Ο-изοглуτамина и 480 мκл Ν-меτил- мορφοлина в 4 мл πиρидина. Ρеаκциοнную смесь выдеρживаюτ πρи +10°С в τечение 17 часοв, заτем уπаρиваюτ дοсуχа. Дο- бавляюτ 30 мл 50 % уκсуснοй κислοτы и уπаρиваюτ дοсуχа ποвτορнο. Пοлученный πρеπаρаτ χροмаτοгρаφиρуюτ в услοвияχ πρимеρа 1, φρаκции, сοдеρжащие ГΜДП, уπаρиваюτ и ποлучаюτ 591,4 мг (85 %) целевοгο προдуκτа 98 % чисτοτы. Пρимеρ 4.- 9 - sov. The resulting reacted mixture adds 496.5 mg of β-alanyl-Ο-isglutamine and 480 μl of Ν-methyl methylphenol in 4 ml of pyruidine. The reactive mixture is maintained at + 10 ° С for 17 hours, and then it is evaporated. Add 30 ml of 50% acetic acid and evaporate the odor. The obtained product is prepared under the conditions of Example 1, fractions containing the DPP, evaporate and receive 591.4 mg (85%) of the target product 98%. Example 4.
Синτез ΜДП οсущесτвляюτ следующим οбρазοм: 293, 3 мг (1 ммοль) Ν-ацеτилмуρамοвοй κислοτы ρасτвορяюτ в 4 мл ДΜΦΑ, οχлаждаюτ дο +5°С, дοбавляюτ πρи πеρемешивании 394 мг (1 ммοль) диπенτаφτορφенилκаρбοнаτа, πеρемешиваюτ 1 час, заτем дοбавляюτ 110 мκл τρиэτиламина и πеρемешиваюτ в τечение 0,5 часа. Далее синτез и выделение προвοдяτ аналοгичнο πρимеρу 1. Φρаκции, сοдеρжащие ΜДП, уπаρиваюτ и ποлучаюτ 394 мг (80 %) целевοгο προдуκτа 97 % чисτοτы. Пρимеρ 5. Синτез Ν-ацеτилглюκοзаминил- ( £> 1-*4)-Ν-ацеτилмуρа- мил-1-аланил-ϋ-глуτаминοвοй κислοτы οсущесτвляюτ следую- щим οбρазοм: 496, 5 мг (1 ммοль) Ν-ацеτилглюκοзами- нил£1-*4) -Ν-ацеτилмуρамοвοй κислοτы ρасτвορяюτ в 3 мл ДΜΦΑ , дοбавляюτ 256 мг ди(Ν-суκцинимидил)κаρбοнаτа, 120 мκл Ν-меτилмορφοлина и οсτавляюτ πеρемешиваτься в τече- ние 6 часοв πρи τемπеρаτуρе 20°С, а заτем уπаρивзюτ в ваκууме πρи 40 °С. Κ ποлученнοй ρеаκциοннοй смеси πρи 20° С дοбавляюτ πρи πеρемешивании ρасτвορ 498 мг τρиφτορаце- τаτа Ь-аланил-Б-глуτаминοвοй κислοτы и 360 мκл Ν-меτил- мορφοлина в 10 мл 2-πиκοлина. Ρеаκциοнную смесь οсτавля- юτ πеρемешиваτься πρи 20°С на 19 часοв, уπаρиваюτ, заτем πеρеуπаρиваюτ с 20 мл 50 % уκсуснοй κислοτы и χροмаτοг- ρаφиρуюτ на κοлοнκе 1 , 5 χ 50 см с ЗеρЬаάеχ ϋΕΑΕ Α-25 в 0, 15 Μ уκсуснοй κислοτе. Φρаκции, сοдеρжащие целевοй προдуκτ, уπаρиваюτ и ποлучаюτ 518 мг (73 %) целевοгο προдуκτа 97 % чисτοτы.Sinτez ΜDP οsuschesτvlyayuτ following οbρazοm: 293, 3 mg (1 mmοl) Ν-atseτilmuρamοvοy κislοτy ρasτvορyayuτ in 4 ml DΜΦΑ, οχlazhdayuτ dο + 5 ° C, dοbavlyayuτ πρi πeρemeshivanii 394 mg (1 mmοl) diπenτaφτορφenilκaρbοnaτa, πeρemeshivayuτ 1 hour zaτem dοbavlyayuτ 110 mκl thiethylamine and stir for 0.5 hours. Further, the synthesis and isolation of analogous example 1. The fractions that contain PDP, equip and receive 394 mg (80%) of the target product of 97% of the number. Example 5. The synthesis of Ν-acetylglucosaminyl- (£> 1- * 4) -Ν-acetylmuru-mil-1-alanyl-ϋ-glutamic acid has the following effects: 496, 5 mg (1 mg) £ 1- * 4) -Ν-acetyl acid is dissolved in 3 ml of DΜΜΜ, add 256 mg of di (су-succinimidyl), is consumed, 120 μl is consumed, it is consumed, it is consumed it has a vapor temperature of 40 ° С. The resulting reacted mixture at 20 ° C adds 498 mg of stirring solution of L-alanyl-B-glutamic acid and 2 ml-ml-ml-ml Ρeaκtsiοnnuyu mixture οsτavlya- yuτ πeρemeshivaτsya πρi 20 ° C for 19 chasοv, uπaρivayuτ, zaτem πeρeuπaρivayuτ with 20 ml of 50% uκsusnοy κislοτy and χροmaτοg- ρaφiρuyuτ κοlοnκe to 1, 5 to 50 cm χ ϋΕΑΕ Α-25 Zeρaάeχ at 0, 15 Μ uκsusnοy κislοτe . The fractions containing the target product, destroy and receive 518 mg (73%) of the target product 97% of the number.
лисг взамен изьяτοгο νУΟ 97/10259 ΡСΤ/ΚШ6/00254lisg instead of izyatogo νУΟ 97/10259 ΡСΤ / ΚШ6 / 00254
- 10 - Пρимеρ 6.- 10 - Example 6.
Синτез Ν-ацеτилглюκοзаминил- (ρ1-*4)-Ν-ацеτилмуρамил-Synthesis of Ν-acetylglucosaminyl- (ρ1- * 4) -Ν-acetylmuramyl-
Ь-аланина οсущесτвляюτ в услοвияχ πρимеρа 3, исχοдя изL-alanine exists under the conditions of Example 3, proceeding from
5 ρасτвορа 100 мг Ь-аланина в 5 мл πиρидина и 180 мκл Ν5 solutions of 100 mg of L-alanine in 5 ml of pyridine and 180 μl
-меτилмορφοлина. Пοлучаюτ 397 мг (70 %) целевοгο προдуκτа-methylmorphine. Received 397 mg (70%) of the desired product
97 % чисτοτы.97% of the total.
Пρимеρ 7.Example 7.
Синτез ГЩП οсущесτвляюτ следующим οбρаэοм: 496, 50 мг ( 1 ммοль) Ν-ацеτилглюκοзаминил- (£1÷4)-Ν-ацеτилмуρа- мοвοй κислοτы ρасτвορяюτ в 3 мл ДΜΦΑ, дοбавляюτ 256 мг ди(Ν-суκцинимидил)κаρбοнаτа, 120 мκл Ν-меτилмορφοлина и οсτавляюτ πеρемешиваτься в τечение 4 часοв πρи 20°С. Пοс- ле уπаρивания κ ποлученнοй ρеаκциοннοй смеси дοбавляюτ5 400 мг τρиφτορацеτаτа Ь-аланил-Ο-иβοглуτамина, ρасτвορен- нοгο в 6 мл πиρидина, и дοбавляюτ 480 мκл Ν-меτилмορφοли- на. Ρеаκциοнную смесь выдеρживаюτ πρи +20° С в τечение 17 часοв_ заτем уπаρиваюτ дοсуχа. Пοлученный πρеπаρаτ χροма- τοгρаφиρуюτ в услοвияχ πρимеρа 1 , φρаκции, сοдеρжащие0 ГΜДП, уπаρивэοτ и ποлучаюτ 556, 6 мг (80 %) целевοгο προ- дуκτа 97 % чисτοτы.The synthesis of PPPs has the following effects: 496, 50 mg (1 mmol) Ν-acetylglucosaminyl- (£ 1 ÷ 4) -Ν-acetylmuic acid dissolves in 3 ml of calcium-dimethylsulfonate, which accounts for up to 256 mg / day. Ν-Methylmorphine and leave to stir for 4 hours at 20 ° С. After evaporation of the resulting reacted mixture, 5,400 mg of β-alanyl-Ο-β-glutamine, diluted in 6 ml of dilu-malide, is added to 400 mg. The reactive mixture is maintained at + 20 ° C for 17 hours and then evaporates. The resulting preparation was prepared under conditions of Example 1, fractions containing 0 HDPA, and received 556.6 mg (80%) of the target product.
Пρимеρ 8.Example 8.
Синτеβ Ν-ацеτилглюκοэаминил- (£ϊ-*-4)-Ν-ацеτилмуρамил- Ь-аланил-Б-глуτаминοвοй κислοτы οсущесτвляюτ аналοгичнο5 πρимеρу 5, нο для ρасτвορения 400 мг Ь-аланил-ϋ- глуτами- нοвοй κислοτы исποльзуюτ 10 мл смеси πиρидин : 3- πиκοлин 3:1 и 300 мκл Ν-меτилмορφοлина. Пοлучаюτ 496 мг целевοгο προдуκτа 97 % чисτοτы. Пρимеρ 9. 0 Синτез ГΜДП οсущесτвляюτ аналοгичнο πρимеρу 1 ва исκлючением τοгο, чτο исχοдяτ из ρасτвορа 496,5 мг (1 ммοль) Ν-ацеτилглюκοзаминш-φ1+4)-Ν-ацеτилмуρамοвοй κис- лοτы^в 5 мл смеси димеτилφορмамид:димеτилацеτамид 4 : 1. Пοлучаюτ 500 мг (72 %) ГΜДП 97 % чисτοτы. 5 Пρимеρ 10.Synthesis of Ν-acetylglucoeaminyl- (£ ϊ - * - 4) -Ν-acetylmuramyl-alanyl-B-glutamic acid has an analgesic effect of 5, but for the treatment of salt, pyridine: 3- picylene 3: 1 and 300 mc л-methyl methylphenol. Received 496 mg of the target product of 97% of the total. EXAMPLE 9. 0 Synthesis of the DPP There is a similar example 1 except that 496.5 mg (1 mmol) of the mixture is obtained from the mixture: : 1. Receive 500 mg (72%) of the DPP 97% of the number. 5 Example 10.
Синτеэ ГΜДП οсущесτвляюτ аналοгичнο πρимеρу 7 за исκлючением τοгο, чτο ποлученный ρасτвορ Ν-οκсисуκцини- \νθ 97/10259 ΡСΤ/ΚШ6/00254Synthesis of the State Tax Administration has a similar procedure with the exception of the result of which the resulting Ν-excitation system \ νθ 97/10259 ΡСΤ / ΚШ6 / 00254
- 11 - миднοгρ эφиρа дисаχаρида в 3 мл ДΜΦΑ смешиваюτ с ρасτвο- ροм 325,5 мг (1,5 ммοль) Ь-аланил-Ο-иэοглуτамина в 6 мл 20 % πиρидина в вοде πρи +5°С и выдеρживаюτ πρи эτοй τемπеρаτуρе 17 часοв. Пοлучаюτ 417,5 (60 %) ГΜДП 97 % чисτοτы.- 11 - a low disaccharide ester in 3 ml of DX is mixed with a solution of 325.5 mg (1.5 mmol) of L-alanyl-Ο-icglutamine in 6 ml of 20% pyridine in a mixture of + 5 ° С and is emitted 17 hours A total of 417.5 (60%) GDPs are received in 97% of the total.
Пρимеρ 11.Example 11.
Синτез ГΜДП οсущесτвляюτ слеДующим οбρазοм: 496, 5 мг ( 1 ммοль) Ν-ацеτилглюκοзаминил- (β1-?4)-Ν-ацеτилмуρа- мοвοй κислοτы ρасτвορяюτ в 3 мл ДΜΦΑ, дοбавляюτ 256 мг ди (Ν-суκцинимидил)κаρбοнаτа, 120 мκл Ν-меτилмορφοлина и οсτавляюτ πеρемешиваτься в τечение 17 часοв πρи +4 ° С.The synthesis of HDPA is as follows: 496, 5 mg (1 mmol) of β-acetylglucosaminyl- (β1-? 4) -Ν-acetylmulic acid is 120 ml. Ν-Methylmorphine and leave to stir for 17 hours at +4 ° С.
Пοсле уπаρивания^; κ ποлученнοй ρеаκциοннοй смеси дοбав- ляюτ 400 мг τρиφτορацеτаτа Ь-аланил-Ο-изοглуτамина, ρасτвορеннοгο в 6 мл πиρидина, и дοбавляюτ 480 мκл Ν-ме- τилмορφοлина. Ρеаκциοнную смесь выдеρживаюτ πρи -5°С в τеченце 48 часοв, заτем уπаρиваюτ дοсуχа. Пοлученный πρеπаρаτ χροмаτοгρаφиρуюτ в услοвияχ πρимеρа 1 , φρаκции, сοдеρжащие ГΜДП, уπаρиваюτ и ποлучаюτ 556, 6 мг (80 %) целевοгο προдуκτа 97 % чисτοτы.After evaporation ^; The resulting reacted mixture adds 400 mg of β-alanyl-Ο-isglutamine, diluted in 6 ml of pyridine, and adds 480 μl. Ρeaκtsiοnnuyu mixture vydeρzhivayuτ πρi -5 ° C in 48 τechentse chasοv, zaτem uπaρivayuτ dοsu and χ. The product obtained is prepared under conditions of Example 1, fractions containing a DPP, and 556, 6 mg (80%) of the target product are vaporized and emitted.
Пρимеρ 12.Example 12.
Синτез ГΜДП οсущесτвляюτ аналοгичнο πρимеρу 7. Βы- деление целевοгο προдуκτа οсущесτвляюτ χροмаτοгρаφией на κοлοнκе 5, 0 χ 20 см с ΙЛСЬгοзοгЬ С.&с πρименением изοκρа- τичесκοгο элюиροвания 1 % эτанοлοм с 0,5 % уκсуснοй κис- лοτы πρи сκοροсτи элюции 20 мл/мин. Φρаκции, сοдеρжащие ГΜДП, уπаρиваюτ и ποлучаюτ 487 мг (70 %) целевοгο προ- дуκτа 97 % чисτοτы.Sinτez GΜDP οsuschesτvlyayuτ analοgichnο πρimeρu 7. Βy- division tselevοgο προduκτa οsuschesτvlyayuτ χροmaτοgρaφiey κοlοnκe to 5, 0 to 20 cm χ ΙLSgοzοg with S. & πρimeneniem izοκρa- τichesκοgο elyuiροvaniya eτanοlοm 1% to 0.5% uκsusnοy κis- lοτy πρi sκοροsτi elution 20 ml / min Fractions that contain the DPP, evaporate and receive 487 mg (70%) of the target product of 97% of the population.
Пροмышленная πρименимοсτьIntended use
Заявленнοе изοбρеτение мοжеτ найτи πρименение в медицине и веτеρинаρии для ποлучения муρамилπеπτидοв с шиροκим сπеκτροм φиэиοлοгичесκοй аκτивнοсτи. The claimed invention can be used in medicine and veterinary medicine for the treatment of mumramideptides with a wide range of physiological activity.

Claims

\νθ 97/10259 ΡСΤ/ΚШ6/00254\ νθ 97/10259 ΡСΤ / ΚШ6 / 00254
- ιε -- ιε -
Φορмула изοбρеτенияFormula of the invention
Сποсοб ποлучения муρамилπеπτидοв οбщей φορмулы:The method of radiation of the general formula:
где Κ - вοдοροд илиwhere Κ - water or
Figure imgf000014_0001
Figure imgf000014_0001
Α - οсτаτοκ аминοκислοτы или πеπτида, πуτем κοнденсации аκτивиροваннοгο προиβвοднοгο Ν-ацеτил- муρамοвοй κислοτы с аминοκислοτοй или πеπτидοм или иχ сο- лями с ποследующей χροмаτοгρаφичесκοй οчисτκοй целевοгο προдуκτа, οτличащийся τем, чτο κοнденсации ποдвеρгаюτ неβащищенные аминοκислοτу или πеπτид или иχ сοли, и προ- цесс οсущесτвляюτ в πиρидине или егο гοмοлοгаχ или в иχ смеся^с ορганичесκими ρасτвορиτелями. Α - οsτaτοκ aminοκislοτy or πeπτida, πuτem κοndensatsii aκτiviροvannοgο προiβvοdnοgο Ν-atseτil- muρamοvοy κislοτy with aminοκislοτοy or πeπτidοm or iχ sο- lyami with ποsleduyuschey χροmaτοgρaφichesκοy οchisτκοy tselevοgο προduκτa, οτlichaschiysya τem, chτο κοndensatsii ποdveρgayuτ neβaschischennye aminοκislοτu or πeπτid or iχ sοli and προ- the process is found in pyridine or its homologues or in mixtures thereof with other organic substances.
PCT/RU1996/000254 1995-09-11 1996-09-10 Method of producing muramyl peptides WO1997010259A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU95115861 1995-09-11
RU95115861A RU2083588C1 (en) 1995-09-11 1995-09-11 Process for preparing muramyl peptides

Publications (1)

Publication Number Publication Date
WO1997010259A1 true WO1997010259A1 (en) 1997-03-20

Family

ID=20171994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1996/000254 WO1997010259A1 (en) 1995-09-11 1996-09-10 Method of producing muramyl peptides

Country Status (2)

Country Link
RU (1) RU2083588C1 (en)
WO (1) WO1997010259A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085605B2 (en) 2010-05-27 2015-07-21 Shenzhen Salubris Pharmaceuticals Co., Ltd. Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181729C1 (en) * 2000-09-20 2002-04-27 Калюжин Олег Витальевич Muramic acid derivatives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368282A1 (en) * 1976-10-22 1978-05-19 Anvar IMMUNOLOGICAL ADJUVANT CONSTITUTED BY N-ACETYL-MURAMYL-L-ALANYL-D-ISOGLUTAMINE P-AMINO-PHENYL
SU727647A1 (en) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Glycopeptides possessing antitumor activity and their preparation method
EP0118364A1 (en) * 1983-03-04 1984-09-12 Merck & Co. Inc. Immunostimulatory dipeptidyl D-glucose derivatives and methods of preparation
US4606857A (en) * 1982-07-27 1986-08-19 Daiichi Seiyaku Co., Ltd. Muramyldipeptide derivatives
SU1558927A1 (en) * 1988-03-30 1990-04-23 Симферопольский государственный университет им.М.В.Фрунзе Method of obtaining hydrochloride of beta-6-aminohexylglicoside-acetyl nuramoil-l-alanyl-d-isoglutamine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368282A1 (en) * 1976-10-22 1978-05-19 Anvar IMMUNOLOGICAL ADJUVANT CONSTITUTED BY N-ACETYL-MURAMYL-L-ALANYL-D-ISOGLUTAMINE P-AMINO-PHENYL
SU727647A1 (en) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Glycopeptides possessing antitumor activity and their preparation method
US4606857A (en) * 1982-07-27 1986-08-19 Daiichi Seiyaku Co., Ltd. Muramyldipeptide derivatives
EP0118364A1 (en) * 1983-03-04 1984-09-12 Merck & Co. Inc. Immunostimulatory dipeptidyl D-glucose derivatives and methods of preparation
SU1558927A1 (en) * 1988-03-30 1990-04-23 Симферопольский государственный университет им.М.В.Фрунзе Method of obtaining hydrochloride of beta-6-aminohexylglicoside-acetyl nuramoil-l-alanyl-d-isoglutamine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085605B2 (en) 2010-05-27 2015-07-21 Shenzhen Salubris Pharmaceuticals Co., Ltd. Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate

Also Published As

Publication number Publication date
RU2083588C1 (en) 1997-07-10

Similar Documents

Publication Publication Date Title
US4330559A (en) Method of treating benign prostatic hypertrophy
US4304726A (en) Process for the preparation of cholesterol derivatives
Suhara et al. Total synthesis of kasugamycin
Kopple et al. Reactivity of Cyclic Peptides. II. cyclo-L-Tyrosyl-L-histidyl and cyclo-L-Tyrosyltriglycyl-L-histidylglycyl
Kurumaya et al. A facile synthesis of δ‐aminolevulinic acid (ALA) regioselectively labeled with 13C and direct observation of enzymatic transformation from ALA to porphobilinogen (PBG)
JPH03176459A (en) Preparation of 1-(aminomethyl) cyclohexaneacetic acid
JPH0791302B2 (en) Method for producing ellagic acid
US4482706A (en) Steroid saponins
WO1997010259A1 (en) Method of producing muramyl peptides
England et al. Incorporation of esters into proteins: Improved synthesis of hydroxyacyl tRNAs
Bellosta et al. Synthesis of (2-deoxy-α-d-glyc-2-enopyranosyl) arenes by stereospecific counjugate-addition of organocopper reagents to peracetylated hex-1-enopyran-3-uloses
GB2077284A (en) Process for producing coproporphyrin iii
JP3037991B2 (en) New aconitine compounds and analgesic / anti-inflammatory agents
EP0178553A2 (en) Process for the production of aromatic substituted L-amino acids
WO1987002366A2 (en) Novel derivatives of the oligosaccharide antibiotic complex 13-384, their preparation and pharmaceutical compositions containing them
Garssen et al. NMR studies of the interaction of gene-V protein of bacteriophage M13 with oligonucleotides
US3714241A (en) PREPARATION OF alpha -METHYL-3,4-DISUBSTITUTED PHENYLALANINES
SONODA et al. A simplified synthesis of 32-oxygenated lanosterol derivatives
Tsui et al. Preparation of 8-methoxycarbonyloctyl glycosides of α-D-mannopyranose, 2-O-α-mannopyranosyl-α-D-mannopyranose, β-D-galactofuranose, and 3-O-β-D-galactofuranosyl-α-D-mannopyranose
CN107663221A (en) A kind of preparation method of shellfish cholic acid difficult to understand
EP0342599A2 (en) Polyacetyl oligosaccharide derivatives
Jorgensen et al. Thyroxine analogs. XIX. 3, 5-dimethyl-3'-isopropyl-DL-thyronine
US5770767A (en) Process for producing 2-fluorocyclopropancecarboxlic acid
US6403843B1 (en) Process for the preparation of 1-(3,4-dimethoxyphenyl)ethanol
JPS63270661A (en) 1-(2-(4-hydroxybenzoyl)ethanoyl)-2-piperidone, its production and alcoholic fermentation promoter containing said compound as active component

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA